EWEdwards Lifesciences Corp

NYSE edwards.com


$ 63.67 $ -0.10 (-0.16 %)    

Tuesday, 30-Jul-2024 15:59:52 EDT
QQQ $ 455.87 $ -6.37 (-1.37 %)
DIA $ 407.51 $ 1.90 (0.47 %)
SPY $ 539.90 $ -2.76 (-0.51 %)
TLT $ 93.85 $ 0.36 (0.39 %)
GLD $ 222.54 $ 2.20 (1 %)
$ 63.64
$ 63.65 x 100
-- x --
-- - --
$ 58.93 - $ 96.12
9,088,778
na
38.44B
$ 1.17
$ 27.19
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-29-2024 03-31-2024 10-Q
2 02-12-2024 12-31-2023 10-K
3 10-27-2023 09-30-2023 10-Q
4 07-28-2023 06-30-2023 10-Q
5 04-28-2023 03-31-2023 10-Q
6 02-13-2023 12-31-2022 10-K
7 10-28-2022 09-30-2022 10-Q
8 07-29-2022 06-30-2022 10-Q
9 04-28-2022 03-31-2022 10-Q
10 02-14-2022 12-31-2021 10-K
11 10-29-2021 09-30-2021 10-Q
12 07-30-2021 06-30-2021 10-Q
13 04-28-2021 03-31-2021 10-Q
14 02-12-2021 12-31-2020 10-K
15 10-26-2020 09-30-2020 10-Q
16 07-27-2020 06-30-2020 10-Q
17 04-28-2020 03-31-2020 10-Q
18 02-14-2020 12-31-2019 10-K
19 10-25-2019 09-30-2019 10-Q
20 07-26-2019 06-30-2019 10-Q
21 04-26-2019 03-31-2019 10-Q
22 02-15-2019 12-31-2018 10-K
23 10-26-2018 09-30-2018 10-Q
24 07-27-2018 06-30-2018 10-Q
25 04-27-2018 03-31-2018 10-Q
26 02-16-2018 12-31-2017 10-K
27 10-27-2017 09-30-2017 10-Q
28 07-28-2017 06-30-2017 10-Q
29 04-28-2017 03-31-2017 10-Q
30 02-17-2017 12-31-2016 10-K
31 10-28-2016 09-30-2016 10-Q
32 07-29-2016 06-30-2016 10-Q
33 04-29-2016 03-31-2016 10-Q
34 02-19-2016 12-31-2015 10-K
35 10-29-2015 09-30-2015 10-Q
36 07-29-2015 06-30-2015 10-Q
37 04-29-2015 03-31-2015 10-Q
38 02-20-2015 12-31-2014 10-K
39 10-31-2014 09-30-2014 10-Q
40 08-04-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wolfe-research-upgrades-edwards-lifesciences-to-peer-perform

Wolfe Research analyst Mike Polark upgrades Edwards Lifesciences (NYSE:EW) from Underperform to Peer Perform.

 ford-stellantis-and-dell-are-among-top-12-large-cap-losers-last-week-july-21-july-27-are-the-others-in-your-portfolio

Top 10 worst performers last week: EW (-28.05%), F (-19.12%), STM (-17.60%), TER (-16.25%), MBLY (-14.61%), STLA (-13.07%), VRT...

 barclays-maintains-overweight-on-edwards-lifesciences-lowers-price-target-to-90

Barclays analyst Matt Miksic maintains Edwards Lifesciences (NYSE:EW) with a Overweight and lowers the price target from $10...

 goldman-sachs-maintains-buy-on-edwards-lifesciences-lowers-price-target-to-91

Goldman Sachs analyst David Roman maintains Edwards Lifesciences (NYSE:EW) with a Buy and lowers the price target from $107 ...

 td-cowen-downgrades-edwards-lifesciences-to-hold-lowers-price-target-to-70

TD Cowen analyst Joshua Jennings downgrades Edwards Lifesciences (NYSE:EW) from Buy to Hold and lowers the price target from...

 edwards-lifesciences-stock-tumbles-highlights-slowdown-in-tavr-business

Edwards Lifesciences reported Q2 results, sales increased 7% to $1.632B, TAVR sales grew 5%, company to acquire JenaValve and E...

 wells-fargo-maintains-overweight-on-edwards-lifesciences-lowers-price-target-to-90

Wells Fargo analyst Larry Biegelsen maintains Edwards Lifesciences (NYSE:EW) with a Overweight and lowers the price target f...

 stocks-rebound-as-us-economy-flexes-muscles-small-caps-rally-gold-falls-whats-driving-markets-thursday

Wall Street strongly rebounded Thursday after Wednesday’s slump, driven by stronger-than-expected economic growth in the last q...

 evercore-isi-group-maintains-in-line-on-edwards-lifesciences-lowers-price-target-to-76

Evercore ISI Group analyst Vijay Kumar maintains Edwards Lifesciences (NYSE:EW) with a In-Line and lowers the price target f...

 deutsche-bank-maintains-buy-on-edwards-lifesciences-lowers-price-target-to-85

Deutsche Bank analyst Pito Chickering maintains Edwards Lifesciences (NYSE:EW) with a Buy and lowers the price target from $...

 rbc-capital-maintains-outperform-on-edwards-lifesciences-lowers-price-target-to-85

RBC Capital analyst Shagun Singh maintains Edwards Lifesciences (NYSE:EW) with a Outperform and lowers the price target from...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION